Drugs / BALORAMOTIDE
BALORAMOTIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02833506 | Dec 2017 → Aug 2018 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, uterine adnexa cancer | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BALORAMOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298083 ↗ |
| Known as | Baloramotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298083 ↗ |
| Known as | Lage-2, recombinant | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298083 ↗ |
| Known as | Recombinant NY-ESO-1 Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02833506 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant NY-ESO-1 Protein” NCT02833506 ↗ |
| Route | Subcutaneous | “Given recombinant NY-ESO-1 protein SC” NCT02833506 ↗ |